| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Min Zhang | |
| Hui Yuan | |||
| Rui Dong | |||
| Yijie Zheng | |||
| Shan Zheng | |||
| Andrew Soh | |||
| Qunying Hu | |||
| P2860 | cites work | Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis | Q24597542 |
| The Role of Galectin-3 in the Kidneys | Q26752754 | ||
| Galectin-3 in heart failure pathology--"another brick in the wall"? | Q26801422 | ||
| Galectin-3 in angiogenesis and metastasis. | Q27687444 | ||
| Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition | Q27714964 | ||
| A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model | Q27726385 | ||
| Up-regulation of galectin-3 in acute renal failure of the rat | Q28344724 | ||
| Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. | Q30587543 | ||
| Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma | Q33631354 | ||
| Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure | Q34102031 | ||
| Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma | Q34167262 | ||
| Galectin-3--a jack-of-all-trades in cancer | Q34221519 | ||
| Galectin-3 as a marker and potential therapeutic target in breast cancer | Q34257030 | ||
| Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma | Q34265995 | ||
| Expression of galectin-3 in gastric adenocarcinoma | Q34272154 | ||
| Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair | Q34338521 | ||
| Ablation of galectin-3 induces p27(KIP1)-dependent premature senescence without oncogenic stress | Q34413483 | ||
| Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. | Q34474679 | ||
| Galectin-3: an open-ended story | Q34494555 | ||
| Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure | Q34997796 | ||
| Therapy of experimental NASH and fibrosis with galectin inhibitors | Q35075568 | ||
| Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis | Q35166192 | ||
| The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists | Q35191679 | ||
| Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure | Q41731823 | ||
| Can be galectin-3 a novel marker in determining mortality in hemodialysis patients? | Q41736786 | ||
| The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. | Q41744993 | ||
| Focus on Molecules: Galectin-3 | Q41954196 | ||
| Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer | Q42177420 | ||
| Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function | Q42191449 | ||
| Immunochemiluminescent detection of galectin-3 in tumoral tissue from prostate. | Q42580165 | ||
| The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty | Q43440923 | ||
| Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer | Q43559327 | ||
| Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation | Q44053611 | ||
| Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials | Q44080331 | ||
| Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. | Q44118879 | ||
| Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients | Q44253238 | ||
| Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study | Q44480518 | ||
| Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence | Q44523706 | ||
| Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma | Q44833175 | ||
| The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively | Q45129579 | ||
| Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior | Q45189766 | ||
| Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction | Q45202266 | ||
| Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma | Q45853721 | ||
| Galectin-3 and Soluble ST2 and Kidney Function Decline in Older Adults: The Cardiovascular Health Study (CHS). | Q46506580 | ||
| Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease | Q46557284 | ||
| Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results | Q46699762 | ||
| The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure | Q46867879 | ||
| Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules | Q46982250 | ||
| Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors | Q47208349 | ||
| Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. | Q48035204 | ||
| Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. | Q48546353 | ||
| Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure. | Q48575472 | ||
| Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial | Q48750580 | ||
| GALECTIN-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA. | Q49162730 | ||
| Up-regulation of galectin-3 and Sambucus nigra agglutinin binding site is associated with invasion, metastasis and poor-progression of the gallbladder adenocarcinoma | Q50174633 | ||
| Galectin-3 Predicts Left Ventricular Remodeling of Hypertension | Q86955911 | ||
| Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study | Q87155350 | ||
| Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients | Q87160068 | ||
| Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients | Q87341099 | ||
| Long-term biological variability of galectin-3 after heart transplantation | Q87385794 | ||
| Expression and clinical significance of galectin-3 in osteosarcoma | Q87790701 | ||
| Galectin-3 and PTEN expression in pancreatic ductal adenocarcinoma, pancreatic neuroendocrine neoplasms and gastrointestinal tumors on fine-needle aspiration cytology | Q87934701 | ||
| Relationship of galectin-3 to left ventricular geometry and hypertrophy in chronic hemodialysis patients | Q88069565 | ||
| Assessment of relationship between galectin-3 and ambulatory ECG-based microvolt T-wave alternans in sustained systolic-diastolic hypertension patients | Q89300184 | ||
| Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis | Q89305965 | ||
| Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential | Q95579418 | ||
| Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). | Q35206146 | ||
| Serum galectin-3 as a potential marker for gastric cancer | Q35207994 | ||
| Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? | Q35286926 | ||
| Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation | Q35432573 | ||
| Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma | Q35563015 | ||
| Galectin 3 for the diagnosis of bladder cancer. | Q35616489 | ||
| Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies | Q36003071 | ||
| Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. | Q36035702 | ||
| Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation | Q36052222 | ||
| Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation | Q36101399 | ||
| Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms | Q36343453 | ||
| Serum Galectin-3: diagnostic value for papillary thyroid carcinoma | Q36358669 | ||
| Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure? | Q36611468 | ||
| Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure | Q36757833 | ||
| Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms | Q36831011 | ||
| Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community | Q36877555 | ||
| Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation | Q36877769 | ||
| Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites | Q36956715 | ||
| Galectin-3: a possible complementary marker to the PSA blood test | Q37038393 | ||
| Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients | Q37077973 | ||
| Elevated galectin-3 precedes the development of CKD | Q37119904 | ||
| Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes | Q37164851 | ||
| Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells | Q37299331 | ||
| Prognostic value of plasma galectin-3 levels after aneurysmal subarachnoid hemorrhage | Q37339791 | ||
| Role for Galectin-3 in Calcific Aortic Valve Stenosis. | Q37556207 | ||
| Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. | Q37696115 | ||
| The pleiotropic effects of galectin-3 in neuroinflammation: a review | Q38073036 | ||
| Galectin-3 in diabetic patients | Q38221153 | ||
| Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients | Q38309028 | ||
| Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis | Q38314021 | ||
| Galectin-3 inhibition prevents adipose tissue remodelling in obesity. | Q38382993 | ||
| Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance | Q38388971 | ||
| Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors | Q38404012 | ||
| Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension | Q38410318 | ||
| Galectin-3 and cardiac function in survivors of acute myocardial infarction. | Q38454450 | ||
| Galectin-3 and post-myocardial infarction cardiac remodeling. | Q38534975 | ||
| Galectin-3 in autoimmunity and autoimmune diseases | Q38542678 | ||
| Galectin 3 as a guardian of the tumor microenvironment | Q38564732 | ||
| Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure | Q38687046 | ||
| Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis | Q38727024 | ||
| Galectin-3: A key player in arthritis. | Q38847703 | ||
| High Plasma Levels of Galectin-3 Are Associated with Increased Risk for Stroke after Carotid Endarterectomy | Q38915953 | ||
| Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population. | Q38921176 | ||
| Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer | Q38950425 | ||
| Role of galectin-3 in autoimmune and non-autoimmune nephropathies | Q38964155 | ||
| Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma. | Q38983451 | ||
| Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure | Q39015148 | ||
| Evaluation of Annexin A7, Galectin-3 and Gelsolin as possible biomarkers of hepatocarcinoma lymphatic metastasis | Q39023762 | ||
| Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice | Q39191329 | ||
| Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis | Q39251941 | ||
| Diagnostic and prognostic value of galectin-3, serum creatinine, and cystatin C in chronic kidney diseases. | Q39303610 | ||
| Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates | Q39424439 | ||
| Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium | Q39470886 | ||
| Clinical significance of Galectin-3 in clear cell renal cell carcinoma | Q39725948 | ||
| Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients | Q40085529 | ||
| Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction | Q40362335 | ||
| Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study | Q40615816 | ||
| Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage | Q40616519 | ||
| Soluble ST2 and galectin-3 in pediatric patients without heart failure | Q40638926 | ||
| Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral artery disease and participants with normal ankle-brachial index | Q40765198 | ||
| Determinants and prognostic value of Galectin-3 in patients with aortic valve stenosis | Q40898595 | ||
| Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease | Q41002506 | ||
| Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival | Q41018493 | ||
| Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties | Q41111574 | ||
| Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study | Q41151739 | ||
| Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation | Q41203031 | ||
| The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation | Q41385684 | ||
| Diagnostic and Prognostic Significance of Serum and Tissue Galectin 3 Expression in Patients with Carcinoma of the Bladder | Q41661749 | ||
| Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping. | Q50230482 | ||
| Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction. | Q50657992 | ||
| Correlations between echocardiographic parameters of right ventricular dysfunction and Galectin-3 in patients with chronic obstructive pulmonary disease and pulmonary hypertension. | Q50759276 | ||
| Short- and Long-term Biologic Variability of Galectin-3 and Other Cardiac Biomarkers in Patients with Stable Heart Failure and Healthy Adults. | Q50961741 | ||
| Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. | Q50994916 | ||
| Renal function largely influences Galectin-3 prognostic value in heart failure. | Q50995380 | ||
| Predictive value of plasma galectin-3 in patients with chronic heart failure. | Q51005416 | ||
| Circulating and tissue galectin-1 and galectin-3 in colorectal carcinoma: association with clinicopathological parameters, serum CEA, IL-17 and IL23. | Q51448643 | ||
| RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. | Q51518944 | ||
| Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction. | Q51521537 | ||
| Clinical benefits of natriuretic peptides and galectin-3 are maintained in old dyspnoeic patients. | Q51525964 | ||
| New onset atrial fibrillation is associated with elevated galectin-3 levels. | Q51568519 | ||
| Galectin-3, Cardiac Function, and Fibrosis. | Q51614488 | ||
| A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva. | Q51684100 | ||
| Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. | Q52139416 | ||
| Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. | Q52140822 | ||
| The Relationship between Galectin-3 and Different Patterns of Ventricular Geometry Remodelling in Aortic Valve Stenosis. | Q52147262 | ||
| Galectin-3 and prediction of therapeutic response to renal sympathetic denervation. | Q52852604 | ||
| The relation among aldosterone, galectin-3, and myocardial fibrosis: a prospective clinical pilot follow-up study. | Q53099098 | ||
| The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression. | Q53099826 | ||
| Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients. | Q53131400 | ||
| Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. | Q53141520 | ||
| Can galectin-3 be a useful marker for conventional papillary thyroid microcarcinoma? | Q53180493 | ||
| The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. | Q53183087 | ||
| Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. | Q53205052 | ||
| Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? | Q53233664 | ||
| Temporal expression of galectin-3 following myocardial infarction. | Q53621883 | ||
| Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. | Q53630691 | ||
| Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. | Q53766231 | ||
| Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system. | Q54697325 | ||
| Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals | Q57832125 | ||
| Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules | Q58005853 | ||
| Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex | Q73003369 | ||
| The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells | Q73336750 | ||
| Embryonic implantation in galectin 1/galectin 3 double mutant mice | Q74498015 | ||
| Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions | Q83997734 | ||
| Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study | Q84811190 | ||
| Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms | Q85330513 | ||
| Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients | Q85335269 | ||
| Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid | Q85760695 | ||
| Galectin-3 and plasma cytokines in patients with acute myocardial infarction | Q85791700 | ||
| Galectin-3, Carotid Plaque Vulnerability, and Potential Effects of Statin Therapy | Q86132126 | ||
| Effects of persistent atrial fibrillation on serum galectin-3 levels | Q86565477 | ||
| The Association of Serum Galectin-3 Levels with Atrial Electrical and Structural Remodeling | Q86740856 | ||
| Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy | Q86776867 | ||
| Evaluation of galectin-3 levels in acute coronary syndrome | Q86831580 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart disease | Q190805 |
| biomarker | Q864574 | ||
| kidney disease | Q1054718 | ||
| neoplasm | Q1216998 | ||
| Galectin 3 | Q3094567 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 599-614 | |
| P577 | publication date | 2017-12-05 | |
| 2018-02-01 | |||
| P1433 | published in | International Journal of Molecular Medicine | Q6051492 |
| P1476 | title | Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). | |
| P478 | volume | 41 |
| Q90069019 | Association between Galectin-3 levels within central and peripheral venous blood, and adverse left ventricular remodelling after first acute myocardial infarction |
| Q90134675 | Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3 |
| Q64065696 | Elevated Platelet Galectin-3 and Rho-Associated Protein Kinase Activity Are Associated with Hemodialysis Arteriovenous Shunt Dysfunction among Subjects with Diabetes Mellitus |
| Q91644019 | FOXD1 and Gal-3 Form a Positive Regulatory Loop to Regulate Lung Cancer Aggressiveness |
| Q58774110 | Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas |
| Q47190193 | Galectin-3 and Cancer Stemness. |
| Q90073141 | Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases |
| Q52340243 | Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. |
| Q48159180 | Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. |
| Q64059939 | Galectins in the Pathogenesis of Cerebrovascular Accidents: An Overview |
| Q90101887 | Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy |
| Q112639555 | Integrated Analysis of DNA Repair Genes Identifies SLC6A1 as a New Marker for the Clinical Outcome of Patients with Colorectal Cancer |
| Q96304831 | LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages |
| Q90333296 | Non-classical role of Galectin-3 in cancer progression: Translocation to nucleus by carbohydrate-recognition independent manner |
| Q90515053 | Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum Galectin-3 level |
| Q99565582 | Quinoline-Pyrazole Scaffold as a Novel Ligand of Galectin-3 and Suppressor of TREM2 Signaling |
| Q92130499 | The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children |
Search more.